The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The group is validating a next-generating sequencing assay that detects EGFR mutations in ultrashort circulating tumor DNA in matched plasma and saliva samples.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
